Evidence map›Paper›PMID 31745296›Full record

ArticleOncogene2020

Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.

Victoria Cluzet, Marie M Devillers, Florence Petit, Stéphanie Chauvin, Charlotte M François, Frank Giton, Catherine Genestie, Nathalie di Clemente, Joëlle Cohen-Tannoudji, Céline J Guigon

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Zebrafish as an emerging model to study gonad development.Computational and structural biotechnology journal · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Victoria CluzetSorbonne Paris Cité, Université Paris-Diderot, CNRS, Inserm, Biologie Fonctionnelle et Adaptative UMR 8251, Physiologie de l'Axe Gonadotrope U1133, Paris, France.
Marie M DevillersSorbonne Paris Cité, Université Paris-Diderot, CNRS, Inserm, Biologie Fonctionnelle et Adaptative UMR 8251, Physiologie de l'Axe Gonadotrope U1133, Paris, France.
Florence PetitSorbonne Paris Cité, Université Paris-Diderot, CNRS, Inserm, Biologie Fonctionnelle et Adaptative UMR 8251, Physiologie de l'Axe Gonadotrope U1133, Paris, France.
Stéphanie ChauvinSorbonne Paris Cité, Université Paris-Diderot, CNRS, Inserm, Biologie Fonctionnelle et Adaptative UMR 8251, Physiologie de l'Axe Gonadotrope U1133, Paris, France.
Charlotte M FrançoisSorbonne Paris Cité, Université Paris-Diderot, CNRS, Inserm, Biologie Fonctionnelle et Adaptative UMR 8251, Physiologie de l'Axe Gonadotrope U1133, Paris, France.
Frank GitonAP-HP, Pôle Biologie-Pathologie Henri Mondor, Inserm IMRB U955 eq07, Créteil, France.
Catherine GenestieDépartement de Pathologie, Institut Gustave Roussy, Villejuif, France.
Nathalie di ClementeSorbonne Université, Inserm, Centre de Recherche Saint Antoine (CRSA), IHU ICAN, Paris, France.
Joëlle Cohen-TannoudjiSorbonne Paris Cité, Université Paris-Diderot, CNRS, Inserm, Biologie Fonctionnelle et Adaptative UMR 8251, Physiologie de l'Axe Gonadotrope U1133, Paris, France.
Céline J GuigonSorbonne Paris Cité, Université Paris-Diderot, CNRS, Inserm, Biologie Fonctionnelle et Adaptative UMR 8251, Physiologie de l'Axe Gonadotrope U1133, Paris, France. celine.guigon@univ-paris-diderot.fr.ORCID http://orcid.org/0000-0002-4489-4304
Centre National de la Recherche Scientifique · FRInserm · FRInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian granulosa cell tumors (GCTs) are indolent tumors of the ovary affecting women at all ages and potentially displaying late recurrence. Even if there is still little information regarding the mechanisms involved in GCT development and progression, FOXL2 would be a major tumor suppressor gene in granulosa cells. We analyzed the mechanisms underlying GCT initiation and progression by using mice with targeted expression of SV40 large T-antigen in granulosa cells (AT mouse), which develop GCTs. Consistent with patients, AT mice with developing GCTs displayed increased levels in circulating anti-Müllerian hormone (AMH), estradiol and androgens, as well as decreased FOXL2 protein abundance. Very few mice developed metastases (1 out of 30). In situ analyses revealed that GCT initiation resulted from both increased granulosa cell survival and proliferation in large antral follicles. Tumorigenesis was associated with the combined inactivation of p53 and Rb pathways, as shown by the impaired expression of respective downstream targets regulating cell apoptosis and proliferation, i.e., Bax, Bak, Gadd45a, Ccna2, Ccne1, E2f1, and Orc1. Importantly, the expression of FOXL2 was still present in newly developed GCTs and its downregulation only started during GCT growth. Collectively, our experiments provide evidence that disrupted p53/Rb signaling can drive tumor initiation and growth. This model challenges the current paradigm that impaired FOXL2 signaling is a major switch of granulosa cell tumorigenesis, albeit possibly contributing to tumor growth.

Indexed as

AnimalsCarcinogenesisCells, CulturedDown-RegulationFemaleForkhead Box Protein L2Granulosa CellsGranulosa Cell TumorHumansMiceMice, TransgenicRetinoblastoma ProteinTumor Suppressor Protein p53Forkhead Box Protein L2Foxl2 protein, mouseRetinoblastoma ProteinTrp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID31745296
OpenAlexW2990325466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.